BR112016009443A8 - moduladores do receptor de nmda, pró-drogas e seus sais - Google Patents

moduladores do receptor de nmda, pró-drogas e seus sais Download PDF

Info

Publication number
BR112016009443A8
BR112016009443A8 BR112016009443A BR112016009443A BR112016009443A8 BR 112016009443 A8 BR112016009443 A8 BR 112016009443A8 BR 112016009443 A BR112016009443 A BR 112016009443A BR 112016009443 A BR112016009443 A BR 112016009443A BR 112016009443 A8 BR112016009443 A8 BR 112016009443A8
Authority
BR
Brazil
Prior art keywords
compounds
prodrugs
salts
nmda receptor
receptor modulators
Prior art date
Application number
BR112016009443A
Other languages
English (en)
Inventor
Amin Khan M
Original Assignee
Naurex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Naurex Inc filed Critical Naurex Inc
Publication of BR112016009443A8 publication Critical patent/BR112016009443A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

são revelados compostos tendo potência intensificada na modulação de atividade de receptor de nmd a. tais compostos são contemplados para uso no tratamento de doenças e distúrbios, tal como aprendizado, atividades cognitivas e analgesia, particularmente em aliviar e/ou reduzir dor neuropática. formulações disponíveis oralmente e outras formas de fornecimento farmaceuticamente aceitáveis dos compostos, incluindo formulações intravenosas, são também reveladas.
BR112016009443A 2013-10-28 2014-10-27 moduladores do receptor de nmda, pró-drogas e seus sais BR112016009443A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896308P 2013-10-28 2013-10-28
PCT/US2014/062367 WO2015065891A1 (en) 2013-10-28 2014-10-27 Nmda receptor modulators and prodrugs, salts, and uses thereof

Publications (1)

Publication Number Publication Date
BR112016009443A8 true BR112016009443A8 (pt) 2020-03-24

Family

ID=53004986

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009443A BR112016009443A8 (pt) 2013-10-28 2014-10-27 moduladores do receptor de nmda, pró-drogas e seus sais

Country Status (15)

Country Link
US (2) US9745342B2 (pt)
EP (2) EP3062810A4 (pt)
JP (1) JP6603668B2 (pt)
KR (1) KR20160077153A (pt)
CN (2) CN105764522A (pt)
AU (2) AU2014342624A1 (pt)
BR (1) BR112016009443A8 (pt)
CA (1) CA2928701A1 (pt)
CL (2) CL2016001001A1 (pt)
IL (1) IL245302B (pt)
MX (2) MX2016005510A (pt)
RU (1) RU2016119830A (pt)
SA (1) SA516371037B1 (pt)
SG (2) SG10201810496XA (pt)
WO (1) WO2015065891A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3228313B1 (en) 2013-01-22 2019-09-11 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses of l-4-chlorokynurenine
CN116082461B (zh) * 2022-10-14 2023-11-14 浙江大学 一种具有抗菌活性的小分子肽及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030840A1 (ja) * 2004-09-14 2006-03-23 National Institute Of Advanced Industrial Scienceand Technology ムチン型ペプチドの合成法とｍｕｃ１関連糖ペプチド
US7960506B2 (en) * 2006-12-14 2011-06-14 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) * 2007-02-23 2019-04-16 爱勒让治疗公司 ***大环***
CN102186883B (zh) * 2008-09-18 2016-08-03 西北大学 Nmda受体调节剂和其用途
EP2342221B1 (en) * 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
CN102933226A (zh) * 2010-02-11 2013-02-13 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
KR20140043078A (ko) * 2011-04-27 2014-04-08 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법

Also Published As

Publication number Publication date
CN105764522A (zh) 2016-07-13
CL2020002247A1 (es) 2021-02-05
SG11201603376UA (en) 2016-05-30
MX2016005510A (es) 2017-01-06
SG10201810496XA (en) 2018-12-28
CN112321678A (zh) 2021-02-05
IL245302A0 (en) 2016-06-30
CA2928701A1 (en) 2015-05-07
IL245302B (en) 2020-05-31
US9745342B2 (en) 2017-08-29
KR20160077153A (ko) 2016-07-01
RU2016119830A3 (pt) 2018-07-02
CL2016001001A1 (es) 2016-12-16
EP3062810A1 (en) 2016-09-07
SA516371037B1 (ar) 2018-05-16
MX2021000029A (es) 2021-03-25
AU2020201109A1 (en) 2020-03-05
US10590167B2 (en) 2020-03-17
JP2016537413A (ja) 2016-12-01
EP3564256A1 (en) 2019-11-06
RU2016119830A (ru) 2017-12-04
US20180127466A1 (en) 2018-05-10
WO2015065891A1 (en) 2015-05-07
US20160244485A1 (en) 2016-08-25
AU2014342624A1 (en) 2016-06-02
JP6603668B2 (ja) 2019-11-06
EP3062810A4 (en) 2017-05-03

Similar Documents

Publication Publication Date Title
BR112014009851A8 (pt) moduladores de receptor de nmda e usos dos mesmos
BR112015018092A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112015018089A2 (pt) moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
BR112015017997A8 (pt) amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BRPI0918868B8 (pt) compostos moduladores do receptor de nmda e composições compreendendo os mesmos
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
BR112018073663A2 (pt) moduladores de receptores nmda spiro-lactâmicos e seus usos
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
DOP2017000087A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
BR112016009443A8 (pt) moduladores do receptor de nmda, pró-drogas e seus sais
BR112018007269A2 (pt) compostos de oxa-diazaespiro tendo atividade contra dor
ECSP17025904A (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y métodos de uso de los mismos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2694 DE 23-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.